Will GLP-1 and GIP Peptide Drugs Keep Working Long-Term? Key Questions Remain | Research

The takeaway

Despite impressive short-term results, the long-term sustainability of GLP-1 and GIP peptide agonists is uncertain due to potential β-cell exhaustion and limited trial data beyond 3 years.

3-year max data
The longest randomized trial of incretin agonists is only 3 years — far shorter than the decades many patients will need these peptide drugs

What the researchers found

While GLP-1 and GIP receptor agonists have shown unprecedented benefits — blood sugar control, weight loss, reduced cardiovascular and renal risks, and even diabetes prevention from prediabetes — the review raises serious questions about long-term sustainability. Chronic stimulation of pancreatic β-cells may lead to receptor downregulation and β-cell exhaustion, potentially causing β-cell failure over time. The longest randomized trial data available is only 3 years.

The review also discusses emerging approaches including amylin (which suppresses appetite but can self-aggregate and cause cytotoxicity) and triple agonists combining GLP-1, GIP, and glucagon activity.

Why it matters

Millions of people are now using GLP-1 and GIP peptide drugs for diabetes and obesity, with these medications being hailed as transformative. This review asks the critical question that patients and doctors need answered: will these benefits last? The possibility of β-cell exhaustion from chronic peptide receptor stimulation, combined with concerns about manipulating hunger signaling long-term, suggests the sustainability of incretin therapy is genuinely uncertain.

The numbers in context

3 years = longest RCT duration · GLP-1 + GIP = dual incretin targets · Triple agonists in development (GLP-1 + GIP + glucagon) · Benefits shown on top of metformin or insulin

How the study worked

This was a narrative review synthesizing evidence from randomized clinical trials and mechanistic studies on incretin hormones (GLP-1, GIP), amylin, and glucagon. The authors evaluated current efficacy data alongside theoretical and mechanistic concerns about long-term sustainability.

Who was studied

Review of clinical trial populations with type 2 diabetes, prediabetes, and obesity treated with incretin-based peptide therapies

What this study cannot tell us

As a narrative review, it does not include systematic search methodology or meta-analysis. The sustainability concerns raised are largely theoretical — there is no clinical evidence yet showing β-cell exhaustion from incretin agonists in humans. The 3-year follow-up limitation is real, but the alarmist framing of potential risks is speculative at this stage.

How to read the evidence

This is a narrative review that synthesizes existing trial data and raises mechanistic concerns. It does not present new data or use systematic review methodology. The sustainability concerns are theoretical rather than evidence-based at this point.

When this study was published

Published in 2024, this review is highly timely as GLP-1 and GIP agonists are experiencing explosive growth in prescribing. The sustainability question it raises will likely be answered by ongoing long-term extension studies in the coming years.

The bigger picture

Incretin-based peptide drugs are the fastest-growing drug class globally, with GLP-1 agonists alone projected to reach over $100 billion in annual sales. The question of long-term sustainability is not just medical — it has enormous economic and public health implications. If these drugs lose efficacy over years, millions of patients may need alternative strategies, making the development of next-generation peptide approaches (triple agonists, amylin analogs) critically important.

Questions still open

Will chronic GLP-1/GIP receptor stimulation lead to β-cell exhaustion and loss of drug efficacy over 5-10+ years?
Can triple agonists (GLP-1 + GIP + glucagon) provide more durable benefits than current dual-target approaches?
Should patients on long-term incretin therapy be monitored for signs of β-cell function decline?

Common questions

Could GLP-1 drugs like semaglutide stop working over time?

This review raises the theoretical concern that continuous stimulation of pancreatic β-cells by incretin agonists could eventually lead to receptor downregulation or β-cell exhaustion, reducing drug efficacy. However, no clinical evidence of this has been observed yet — the concern is based on biological mechanisms, and the longest trials (3 years) have shown sustained benefits.

What are triple agonists and could they be better than current GLP-1 drugs?

Triple agonists are next-generation peptide drugs that activate three hormone receptors simultaneously — GLP-1, GIP, and glucagon. By engaging multiple metabolic pathways, they may provide stronger or more durable effects on weight loss and blood sugar control. Several are currently in clinical development as potential successors to current dual-agonist drugs like tirzepatide.

Read the original research

Does Incretin Agonism Have Sustainable Efficacy?

Cells, 13(22)

View on PubMed ↗Publisher’s paper ↗

Citation

Janket, Sok-Ja; Chatanaka, Miyo K; Sohaei, Dorsa; Tamimi, Faleh; Meurman, Jukka H; Diamandis, Eleftherios P. (2024). Does Incretin Agonism Have Sustainable Efficacy?. Cells, 13(22). https://doi.org/10.3390/cells13221842